Developments in the Management of Metastatic HER2-Positive Breast Cancer and Delivery of Patient-Centered Oncology Care

Program Description
Human epidermal growth factor receptor 2 (HER2) expression is a marker of a more aggressive disease and presents in about 25% of breast cancers. The treatment of HER2-positive breast cancer has evolved with increasing availability of HER2-targeted therapies. The appropriate sequencing of therapies for patients with HER2-positive breast cancer can be complex, and pharmacists are integral to ensuring care coordination and providing medication expertise to the multidisciplinary care team. In this program, expert faculty will review recent clinical trial data and guideline recommendations detailing the use of HER2-targeted therapy for first-line treatment. Patient adherence to therapy remains a priority compounded by cost of treatment and concerns of adverse effects of therapy. To ensure optimal patient outcomes, pharmacists must be prepared to make early interventions and assist the oncology care team with identification and management of potential treatment-related adverse effects of HER2-targeted therapies. Oncology pharmacists are positioned to use information gained through this activity to provide education to patients and members of the health care team, monitor drug toxicities, and recommend dose adjustments as appropriate.

Target audience: Health-system, oncology, and specialty pharmacists, physicians, and nurses
Type of activity: Application
Release date: January 25, 2022
Expiration date: March 25, 2022
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Compare and contrast the mechanisms of action and administration of human epidermal growth factor receptor 2 (HER2)-targeted therapies

• Interpret recent literature evaluating therapies in HER2-positive metastatic breast cancer and characterize subsequent implications for changes in practice paradigms

• Identify adverse effect profiles and management strategies in efforts to improve adherence to and patient outcomes associated with HER2-targeted therapy

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Danielle Roman, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms